Raj Kumar Raheja

This inventor holds 25 USPTO granted patents and 4 published patent applications and 9 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Signal Pharmaceuticals, Inc., Celgene Corporation, Array Biopharma Inc.. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Raj Kumar Raheja. Retrieved from https://idiyas.com/inventor/raj-kumar-raheja

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 10.1

ph-index = 6

Forward Citations = 116(Granted Patents)

Company Filing History:

13 out of 169

Signal Pharmaceuticals, Inc.

Orphagen Pharmaceuticals

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Antiproliferative Compounds

Janus Kinase Inhibitors

Aminopurine Compounds

Pharmaceutical Compositions

Pyrrolopyrimidine Compounds

Diaminopyrimidyl Compounds

Inflammatory Disease

Male Contraception

Compounds Compositions

Methods of Treatment

Substituted Compounds

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492177 - RAR-α compounds for inflammatory disease and male contraception (2025-12-09),

2. 11590139 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2023-02-28),

3. 11365184 - Antiproliferative compounds, and their pharmaceutical compositions and uses (2022-06-21),

4. 11241423 - Antiproliferative compounds and methods of use thereof (2022-02-08),

5. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2021-06-08),

6. 10940152 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2021-03-09),

7. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors (2020-08-04),

8. 10646493 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2020-05-12),

9. 10618883 - Antiproliferative compounds, and their pharmaceutical compositions and uses (2020-04-14),

10. 10398700 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2019-09-03),

11. 10227325 - Antiproliferative compounds, and their pharmaceutical compositions and uses (2019-03-12),

12. 10189845 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2019-01-29),

13. 10149849 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2018-12-11),

14. 9968596 - Antiproliferative compounds and methods of use thereof (2018-05-15),

15. 9938254 - Antiproliferative compounds, and their pharmaceutical compositions and uses (2018-04-10),

Title: Innovations and Contributions of Raj Kumar Raheja

Introduction

Raj Kumar Raheja, based in Poway, California, is an accomplished inventor with a significant portfolio of 24 patents. His work primarily focuses on pharmaceutical compounds and their applications in medical treatments, showcasing his contribution to the field of medicinal chemistry.

Latest Patents

Among his latest innovations, Raheja has developed several noteworthy patents, including "Substituted Aminopurine Compounds, Compositions Thereof, and Methods of Treatment Therewith." This patent covers various aminopurine compounds with promising structures that may lead to effective treatments. Additionally, he holds a patent for "Antiproliferative Compounds, and Their Pharmaceutical Compositions and Uses," which details compounds capable of inhibiting cell proliferation, their formulations, and associated methods for production and application.

Career Highlights

Raj Kumar Raheja has made significant strides in the pharmaceutical industry, working for reputable companies like Signal Pharmaceuticals, Inc. and Celgene Corporation. His experiences in these organizations have allowed him to advance his research efforts and drive innovation in drug development.

Collaborations

Throughout his career, Raheja has collaborated with notable colleagues, including Joshua Hansen and Dehua Huang. These partnerships have fostered a collaborative environment that is essential for breakthrough innovations and the successful realization of new pharmaceutical concepts.

Conclusion

Raj Kumar Raheja's contributions to the field of pharmaceutical sciences are both impactful and innovative. With a robust patent portfolio and a history of collaboration with esteemed professionals, he continues to be a driving force in the development of new therapeutic compounds. His work exemplifies the essence of creativity and scientific advancement in medicine.

Profile summary based on public USPTO records.